Fortified Lubricating Eye Drops for Tear Film Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease (DED) are costly, have mixed efficacy, cause patient discomfort, and provide delayed benefits, often leading to ocular burning and discomfort.
Innovation Solution
Ophthalmic pharmaceutical formulations comprising lubricity-promoting ingredients, surfactants, mucoadhesive polymers, and nutritional supplements, formulated as microemulsions or nanoemulsions, to enhance ocular health and comfort by improving tear film stability and nutritional support for corneal epithelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional prescription products are used for dry eye disease, then treatment efficacy is achieved, but cost increases and patient discomfort occurs
Solution Approach 1:
The patent changes the chemical composition parameters by incorporating specific amino acids (arginine, lysine, histidine, glutamine, proline) and vitamins (C, E, A) in defined concentrations to achieve treatment efficacy while reducing ocular burning. The formulation adjusts pH and osmolarity parameters to match tear film composition, thereby improving comfort while maintaining therapeutic effect
Solution Approach 2:
The invention creates a composite ophthalmic formulation combining multiple functional ingredients: amino acids for metabolic support, vitamins for antioxidant protection, and lubricating agents. This composite approach provides both therapeutic efficacy and comfort by integrating multiple beneficial substances in a synergistic formulation
2Reliability
If conventional dry eye treatments are administered, then therapeutic benefit is provided, but benefit delay occurs
Solution Approach 1:
The patent incorporates amino acids and vitamins that serve as pre-formed building blocks for corneal cell metabolism, eliminating the need for gradual synthesis. These pre-positioned nutrients immediately support cellular function and tear film production, accelerating therapeutic benefit while maintaining efficacy
Solution Approach 2:
The formulation provides continuous nutritional support through amino acids and vitamins that sustain corneal epithelial cell metabolism over time. This continuous supply of metabolic substrates ensures persistent therapeutic effect without the intermittent delays associated with conventional treatments that rely on slower physiological adaptation
3Reliability
If nutritional supplementation is added to ophthalmic formulations, then corneal health is improved, but formulation complexity increases
Solution Approach 1:
The patent designs a multi-functional formulation where amino acids serve dual purposes: as building blocks for protein synthesis and as osmoprotectants. Vitamins provide both antioxidant protection and metabolic cofactor functions. This multi-functionality reduces the need for separate additives, simplifying the overall formulation while maintaining comprehensive corneal support
Solution Approach 2:
The invention merges nutritional supplements with lubricating agents and preservative systems into a unified formulation. The amino acid and vitamin components are integrated with the base lubricating formulation, creating a single product that provides both nutritional support and immediate lubrication, thereby reducing formulation complexity compared to separate products
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide improved eye comfort, reduced vision blurring, and enhanced nutritional support, while maintaining a favorable aqueous environment, allowing for effective delivery of active agents and reducing ocular irritation.
Implementation Method 1
surfactant(s) that solubilize oil(s) and/or Ascorbyl Palmitate and/or Vitamin D and/or Vitamin E, assist in lubrication, and assist in easily spreading over hydrophobic surfaces
Implementation Method 2
mucoadhesive polymer(s) that demonstrate shear thinning flow behavior
Implementation Method 3
oil(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication
Implementation Method 4
osmoprotectants
Data Source
AI summary
The invention describes ophthalmic pharmaceutical formulations comprising pharmaceutical ingredients to address DED symptoms. In one aspect of the invention, an ophthalmic pharmaceutical formulation comprises: 1) lubricity-promoting ingredient(s) such as those listed in the FDA over the counter (OTC) monograph for ophthalmics as demulcents and 2) surfactant(s) that solubilize lipids, assist in lubrication, and assist in easily spreading over hydrophobic surfaces; and/or 3) lipid and/or oil ingredient(s) that assist in film formation and the spreading of tear fluid while promoting (or at least not inhibiting) lubrication; and/or 4) mucoadhesive and viscosity promoting polymer(s) that demonstrate shear thinning flow behavior. The pharmaceutical ingredients and osmoprotectant/tonicity ingredients are combined with ingredients that provide direct to the eye nutritional support that is comprehensive in nature. The total nutritional approach uses metabolically important tear fluid amino acids, vitamins, natural antioxidants such as ferulic acid, and both fatty acids/triglycerides and sugar molecules as energy sources. The invention results in both improved eye health and improved dry eye patient comfort.